Annovis Bio shares surge 11.84% intraday as director Hoffman buys $1.5M in stock and company secures U.S. patent for buntanetap.

Annovis Bio surged 11.84% intraday, driven by two key announcements: first, Director Hoffman increased his stake on April 2 by purchasing 713,800 shares at $2.10 each, totaling approximately $1.5 million, raising his ownership to around 27.7%. Second, the company announced it has been granted U.S. Patent No. 12,582,632 B2, covering the use of its oral candidate buntanetap for the prevention and treatment of neurological damage caused by brain infections.